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INTRODUCTION 
Diabetes  mellitus  is  a  group  of  metabolic  disorders  which  are  
characterized by chronic  hyperglycemia  and  associated  disturbance in 
carbohydrate,  fat,  and  protein  metabolism  because  of  absolute   
or  relative  deficiency  in  insulin  secretion  and/or  action.1 
The  long  standing  effects  of  diabetes  include  nephropathy  
leading to  renal  failure, progressive  development  of  retinopathy  
leading  to  potential  blindness, features  of  autonomic  dysfunction,  
sexual dysfunction,  neuropathy  leading  to  foot  ulcers, charcoat  joint, 
amputation. They  are  at  increased  risk  of  cerebrovascular, peripheral   
vascular  and  cardiovascular  diseases  compared  to  general   
population. 
 Due  to  delayed  diagnosis,  lack  of  awareness,  inadequate  
control of  the  disease  and  hypertension,  there  is  a  high  prevalence  
of  diabetes  related  complications  like  retinopathy (18%),  peripheral  
vascular  disease (6.3%), peripheral  neuropathy (26%), peripheral  
neuropathy (26%), overt  nephropathy (2.2%) with  27%  having  
microalbuminuria  and  coronary  artery  disease (21%).Lifestyle   
changes  because  of  modernization  and  urbanization  hasled  to  lack   
of  physical  activity,  increased  stress,  unhealthy  diet  habits  leading   
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to  Obesity,  Overweight  with  high  level  of  insulin  resistance.2 
 Diabetes  is  the  most  common  metabolic  disease  that’s  is  
present  in  each  and  every  part  of  the  world. It  is  the  major  public  
health  challenge  in  the  21st  century. 80 to 90%  of  the  diabetic   
population  is  constituted  by  type  2  diabetes.  In  developing  countries   
including  INDIA,  chronic  metabolic disorders  pose  an  increased   
challenge  to  national  health  than  the  communicable  diseases.3-4 
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AIMS AND OBJECTIVES 
 
1) To  compare  the  glycemic  profile  of  patients  suffering  from   
Rheumatological  diseases  before  and  after  initiating  treatment 
with Hydroxychloroquine. 
 
2) To  analyse  the  effect  of  Hydroxychloroquine  on  blood  glucose  
and  its potential  use  as  an  oral  hypoglycemic  agent  in  
diabetes mellitus.   
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REVIEW OF LITERATURE 
HISTORY OF DIABETES 
Thomas  Willis,  an  Anatomist,  Physician  and  Professor  of  
Natural Philosophy  in  Oxford  University  discovered  diabetes  in  1674  
by   tasting  the  urine  of  people  with  diabetes.5  It  was  described  way   
back in  400  B.C.  by  Susruta  in  India  who  described  it  as   
“HONEYED  URINE”.6  In  1776,  Matthew  Dobson  of  Manchester,  
England  demonstrated  the  presence  of  sugar  in  the  urine  of   
diabetic  individuals  by  boiling   the  urine  to  note  a  crystalline  
residue.  It  had  the  appearance  and  taste  of  “BROWN  SUGAR”.7 
 It  was  thought  that  the  kidneys  are  the  major  source  of  the   
problem,  since  the  most  striking  symptoms  and  signs  were  related  
to  polyuria. In 1788  Thomas  Cawley  reported  shriveled pancreas  with  
stones  in  an  autopsy  of  a  diabetic  person. It  must be  the  first  
published  reference  of  diabetes  relating  the  disease  to  the  pancreas.8 
 Apollinaire  Bouchardat  and  E. Lancearaux  were  the  two  
strongest forces  who  argued  for  a  pancreatic  factor  in  the  causality  
of diabetes. Subsequently  Lanceraux  and  his  students  concluded  that 
two  types  of  diabetes  exists  namely  “Diabete Maigre - Diabetes  of 
Thin”  and  “Diabete  Gras - Diabetes  of  Fat”.9 Joseph  von   Mering  
and  Oscar  Minkoswki  in  1889  did  total  pancreatectomy   on  two  
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dogs and  demonstrated  polyuria. This  was  the  turning  point  in  
history  of  diabetes.  Laguesse  in  1893  drew  the  attention to  
theforgotten  original  observations  of  Langerhans  and  suggested  the  
collections  of  interacinar  cells  of  pancreas  as  a  secretory  gland 
within  pancreas. He  later  named  them  as  islets  of  Langerhans.10 
 Between  1921  and  1922,  Frederick  Banting,  a  surgeon;  
Charles  Best,  a graduate  student;  John  Macleod,  a  physiology  
professor And  J. B. Collip, a skilled chemist  went  on  to  succeed  
infulfilling   of  all  of  the  criteria  for  a  therapeutic  active  insulin. 
They  produced  the  first  successful  insulinpreparation  in  treating  
human  diabetes.11In  1922,  Banting  and  Macleod  were awarded  the  
Nobel  Prize  in  Medicine. Leonard  Thompson, a  14  year  old  boy 
was  the  first  to  receive  the  pancreatic  extract  named  isletin  then. 
 Multiple  milestones  have  been  achieved  after  Banting  and  
Best’s work. Sulfonylureas  were  the  first  oral  hypoglycemic  agents   
introduced in  1955. Alpha  glucosidase  inhibitors  were  widely  used   
in  1980s.  Thiazolidinediones  were  introduced  subsequently  in   
1990s. 
 Glycosylated  hemoglobin  assay  gained  popularity  and  was  
widely used  from  the  late  1970s.  The  property  of  glucose  to  bind  
to hemoglobin  came  to  be  noted  in  1968,  after  the  discovery  by  an  
 investigator  who  claimed  that  a  group  of  his  diabetic  patients  had a  
huge  difference  in  minor  hemog
electrophoresis.12-13
 
BURDEN  OF  DIABETES:
 In  INDIA,  Diabetes  Mellitus  
potential epidemic.
people.14-15  It  is  next  
USA (24  million). 50% of  the
of  the  above  three  countries,  according   to  the  International  Diabetes  
Federation (2013).  Earlier it  was  considered  as  a  disease  of  high  
socio - economic people.  It  was  more  prevalent  in   urban  India.  But  
the  present  scenario  suggests  that  the  disease  affects  the  low  socio 
economic   people  too. There  is  a  marked  rise  in  the  incidence  and  
prevalence  of  diabetes  in  rural  India.
6 
lobin  fraction  in  an  assay  
 
  
is  fast  gaining  the  status  of  a  
 It  is  home  to  more  than  65  million  diabetic  
to  CHINA (98  million)  and  is  followed  by  
 world’s  Diabetic  population  live  
 
 of  
in  one  
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The  highest  prevalence  of  diabetes  is  reported  from  
ERNAKULAM  located in  KERALA (19.5%). The  lowest  prevalence  
is  reported  from  KASHMIR  Valley (6.1%). In TAMILNADU,  
diabetes  prevalence  in  cities  amount  to  16.4%  while,  peri - urban  
villages  document  9.2%. The  prevalence  of  diabetes in  the  rural  
areas  of  economically  better  regions  of  Tamilnadu, Chandigarh  and  
Maharastra  was 7.8%,  8.3%  and  6.5%  respectively. 
 WHO  has  estimated  that  there  will  be  an  increase  in  global 
expenditure  for  diabetes  to  411  billion  dollars  in  the  next  20 years  
from  234  billion  dollars  in  2007. In  INDIA  the  median expenditure  
has  increased  to  9000  rupees  in  2005  from  4200  rupees in  1998.  25 
to  30%  of  the  poor  people’s  income  is  spent  on  health care.16 It  
further  increases  in  coexisting  diabetic  complications.  
 
  
 SPECTRUM OF GLUCOSE HOMEOSTASIS AND 
DIABETES 
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ETIOLOGIC  CLASSIFICATION  OF  DIABETES  
MELLITUS17 
I.TYPE  1  DIABETES: 
Destruction  of  beta  cells, leading to absolute  insulindeficiency. 
A. Immune – mediated. 
B. Idiopathic. 
 
II. TYPE  2  DIABETES:  
It  can  range from predominantly insulin secretory defect  with  
insulin  resistance  to  predominantly insulin resistance  with  relative  
insulin  deficiency. 
 
III. OTHER SPECIFIC TYPES OF DIABETES: 
A. Genetic defect in beta cell development or function 
characterized by mutations in: 
 1. Hepatocyte nuclear transcription factor (HNF) 4α (MODY 1) 
 2. Glucokinase (MODY 2) 
 3. HNF-1α (MODY 3) 
 4. Insulin promoter factor-1 (IPF-1; MODY 4) 
 5. HNF-1β (MODY 5) 
 6. NeuroD1 (MODY 6) 
 7. Mitochondrial DNA 
10 
 
 8. Subunits of ATP-sensitive potassium channel 
9. Proinsulin or insulin 
10. Other pancreatic islet proteins /regulators  such as KLF11, 
GATA4, GATA6 PAX4, BLK,, SLC2A2 (GLUT2), RFX6, GLIS3 
     *MODY : Maturity - Onset  Diabetes  of  the  Young. 
 
B. Genetic defects in action  of  insulin. 
 1. Type A insulin resistance. 
 2. Leprechaunism. 
 3. Rabson – Mendenhall syndrome. 
 4. Lipodystrophy syndromes. 
 
C. Diseases ofexocrinepancreas - pancreatitis, 
pancreatectomy,cystic fibrosis, hemochromatosis, fibrocalculous 
pancreatopathy, neoplasia, mutations  in  carboxyl ester lipase. 
 
 D. Endocrinopathies: Acromegaly, Cushing’s syndrome,  
Glucagonoma,  Pheochromocytoma,  Somatostatinoma,  Aldosteronoma. 
 
E. Drug or chemical  induced: Glucocorticoids,  Pentamidine, 
Nicotinic acid, Vacor (a rodenticide), Diazoxide, Beta  adrenergic  
agonists, Thiazides, Hydantoins, Asparaginase,  Calcineurin and mTOR  
inhibitors, Alpha - interferons, Protease inhibitors, Epinephrine, 
Antipsychotics (atypicals and others). 
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F. Infections: 
 Congenital rubella, Coxsackievirus , Cytomegalovirus. 
 
G. Uncommon forms of immune- mediated diabetes: 
 Anti - insulin receptor antibodies, “stiff-person” syndrome. 
 
H. Genetic syndromes sometimes associated with diabetes: 
Down’s syndrome, Klinefelter’s syndrome,  Wolfram’s syndrome, 
Turner’s syndrome, Myotonic  dystrophy, Friedreich’s ataxia, 
Huntington’s  chorea, 
 Laurence - Moon - Biedl syndrome,  Porphyria, Prader - Willi 
syndrome. 
IV. Gestational Diabetes Mellitus (GDM) 
 The  terms  Insulin  Dependent  Diabetes  Mellitus  and  Non – 
Insulin Dependent  Diabetes  Mellitus  are  obsolete  now. 
 Monogenic  Diabetes  and Maturity  onset  diabetes  of  young   
(MODY)  are  subtype  of  Diabetes  Mellitus.They  are  charecterised by  
Autosomal  Dominant  inheritance,  impaired  insulin  secretion   and  
early  onset  hyperglycemia  usually  less  than  25  years. 
 
GESTATIONAL  DIABETES  MELLITUS: 
 Pregnant  mothers  should  be  routinely  screened  at  24 - 28  
weeks to  detect  GDM. 
12 
 
Carpenter  and  Coustan  classification: 
 American  Diabetes  Association  has  adopted  this  and  GDM  is 
diagnosed  if  any  2  values  cross  the  mentioned  cut-off. 
 100 g  OGTT 75 g  OGTT 
Fasting 95 mg/dl 95 mg/dl 
1 - hour 180 mg/dl 180 mg/dl 
2 - hour 155 mg/dl 155 mg/dl 
3 - hour 140 mg/dl - 
 
WHO  Classification: 
 Fasting  plasma  glucose 2 hour  plasma  glucose 
IGT - 140 - 199 mg/dl 
Diabetes ≥126 mg/dl ≥200 mg/dl 
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ANATOMY AND PHYSIOLOGY  OF  PANCREAS: 
 
 Pancreas  is  a  soft,  lobulated,  elongated  and  a  retroperitoneal  
organ,  wrapping  around  the  second  part  of  duodenum. It  
liestransversely  at  the  level  of  L1  and  L2. Its  15 - 20 cms long,  3 cm  
broad  and  2 cm  thick. It  weighs  around  90 grams. It  derives  its blood  
supply  from  splenic  artery  and  pancreaticoduodenal  arteries. It  drains  
via  splenic  vein  into  portal  vein. It  has  both   sympathetic  and  
parasympathetic  nerve  supply. It  consists  of  both exocrine  and  
endocrine  parts. 18 
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 The  endocrine  part  is  made  up  of  microscopic  elements  called   
Pancreatic  islets  of  Langerhans. They  are  small  islands  of  cells  
distributed  throughout  the  gland. They  appear  most  numerous  in  the  
tail. The  islets  have  various  types  of  cells  of  endocrine  importance. 
Of  the  endocrine  hormones  secreted  by  the  pancreas,  Insulin  and 
Glucagon  play  crucial  role  in  the  normalregulation  of  Glucose, Lipid  
and  protein  metabolism. 
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Endocrine  Pancreatic  Cells  And  Their  Functions: 
Cell type 
Percentage of 
islet cells Hormonal content 
Βeta 60–80 Insulin, IAPP/amylin (thyrotropin-releasing 
hormone, calcitonin gene–related peptide, gastrin, 
pancreastatin) 
Αlpha 15–20 Glucagon (glicentin, TRH, CCK, endorphin, 
glucagon-like polypeptide-1, peptide YY, DKP 
histidyl-proline diketopiperazine, pancreastatin) 
Delta 5–10 Somatostatin (met-enkephalin, CGRP, 
pancreastatin) 
PP 15–20 Pancreatic polypeptide (met-enkephalin, peptide 
YY) 
δ1 <1 Vasoactive intestinal polypeptide 
EC <1 Substance P, serotonin 
G1 <1 Gastrin (adrenocorticotropic hormone-related 
peptides) 
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INSULIN - CHEMISTRY  AND  SYNTHESIS: 
 
 
 
It is  a  polypeptide  hormone. Molecular  weight  -  5808 Da. The  
gene  for  encoding  insulin  INS gene,  is  located  in  the  short   arm  of  
Chromosome  11,  which  has  3  exons  and  two  introns.19 
 It  has  two  chains  connected  by  disulfide  bonds. Porcine  insuli    
differs  from  human  insulin  by  one  aminoacid. 
  
Preproinsulin  is  synthesized  in  endoplasmic  reticulum  of  B  
cells. Molecular  weight 
apparatus. 
 The  molecule  is  folded,  disulfide  
Proinsulin. Molecular  weight 
this  process. Proinsulin  has  no  insulin  activity.
The  Connecting  peptide (C peptide)  permits  folding  and  is  
detached  before  secretion  fr
17 
- 11,500 Da. It  is  transported  to  the  Golgi  
bonds  are  formed  to  make  
- 9000 Da.Two  proteases  are  involved  in  
 
om  the  granules.20 
 
 
 It  is  packed  into  membrane  bound  granules  here.
peptide is  detached  before
microtubular  transportation, th
plasma  membrane.
 The  contents  of  the  granules  are  
90-97%  of  the  content  expelled  from  the  granules  are  insulin  
an  equimolar  amount  of  c
content. 
 Insulin  has  to  
fenestrated endothelium  of  the  neighbouring  capillary.
 The  half  life  of  insulin  is  ve
of   it  binds  to  insulin  receptors.
degraded  by  proteas
degradation  takes  place  mainly 
in  the  muscles,  kidneys  and  other  tissues.
18 
  release  from  the  granules. 
e  granules  are  transferred  
 
then  expelled  by  exocytosis.
-peptide. Proinsulin  forms  the  rest
cross  the  B  cell  basal  lamina  and  the  
 
ry  short. Its  about  5  mins. 
 The  rest  are  internalized
e  namedinsulinase  inside  the  endosomes. 
 in  the  liver  and  to  some  
 
 
 The  c-
Through  
to  the  
 
 with  
 of  the  
Most  
 and  
The  
extent   
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INSULIN RECEPTOR: 
 Insulin  receptor  has  a  molecular  weight  of  about  3,40,000 
kDa. It  consists  of  2 alpha  subunits  that  is  completely  extracellular  
and  2  beta  subunits  which  penetrate  the  membrane,  extending into  
the  cytoplasm. 
 The  IGF - I  receptor  is  very  similar  to  insulin  receptor,  but  
the IGF - II  receptor  is  not. 
 The  beta  subunits  have  Tyrosine  kinase  activity.  Both  subunits   
are  held  together  by  disulfide  linkages. Insulin  binds  to  the  
extracellular  component  and  initiate  the  autophosphorylation  of  
intracellular  beta  subunits. 
 
  
This  in  turn  cause  phosphoryl
located  intracellularly.
 
 
20 
ation  of  many  other  enzymes  
The  half  life  of  the  receptor  is  7  hours.
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FACTORS  AND  CONDITIONS  THAT  INCREASE  INSULIN 
SECRETION:21 
• Increased  blood  glucose. 
• Increased  blood  free  fattyacids. 
• Increased  blood  aminoacids. 
• Gastrointestinal  hormones:  gastrin,  cholecystokinin,  secretin,   
gastric  inhibitory  peptide, glucagon  like  peptide - 1. 
• Neurotransmitters: acetylcholine, vasoactive  intestinal  peptide,  
gastrin  releasing  polypeptide,  Pituitary  adenylate  cyclase       
activating  polypeptide  
• Glucagon. 
• Cortisol. 
• Growth  hormone. 
• Beta adrenergic  stimulation. 
• Adiponectin. 
• Insulin  resistance. 
• Adenine  nucleotides. 
• Divalent  cations. 
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FACTORS  AND  CONDITIONS  THAT  DECREASE  INSULIN  
SECRETION: 
 
• Decreased  blood  glucose. 
• Fasting. 
• Somatostatin - 14,  28. 
• Leptin. 
• Ghrelin. 
• Resistin. 
• Galanin. 
• Neuropeptide Y. 
• Dopamine. 
• Norepinephrine. 
• Alpha  adrenergic  activation. 
 
 
 Intracellular  mechanism  by  which  glucose  stimulates
PRINCIPAL  ACTIONS  OF  INSULIN:
Rapid (seconds): 
 Increased  transport  of  glucose,  aminoacids  and  K+  into  the  
  insulin - sensitive  cells
 
Intermediate (minutes):
• Stimulation  of  protein  synthesis.
• Inhibition  of  protein  degradation.
• Activation  of  glycolytic  enzymes  and  glycogen  synthase.
• Inhibition  of  phosphorylase  and  gluconeogenic  enzymes.
 
 
23 
insulin  release. 
 
.   
 
 
 
 
 
 
 
 
 Delayed (hours): 
Increase  in  mRNAs  for  lipogenic  and  other  enzymes.
 Insulin  is  secreted  in  two  phases  following  the  rise  in  
glucose. 
 
EFFECTS  OF  INSULIN  ON  VARIOUS  TISSUES:
 
General: 
 Increased  cell  growth.
Liver: 
 Decreased  ketogenesis.
 Decreased  glucose  output  due  to  decreased  gluconeogenesis,
increased  glycogen  synthesis  and  increased  glycolysis.
 Increased  protein  synthesis.
 Increased  lipid  synthesis.
24 
 
 
 
 
 
 
22
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Adipose  tissue: 
• Increased glucose entry. 
• Activation  of  lipoprotein  lipase. 
• Inhibition  of  hormone  sensitive  lipase. 
• Increased  glycerol  phosphate  synthesis. 
• Increased  triglyceride  deposition. 
• Increased  fatty  acid  synthesis. 
• Increased  K+  uptake. 
Muscle: 
• Increased  glucose  entry. 
• Increased  glycogen  synthesis. 
• Increased  ketone  uptake. 
• Increased  amino  acid  uptake. 
• Increased  protein  synthesis  in  ribosomes. 
• Decreased  protein  catabolism. 
• Decreased  release  of  gluconeogenic  amino  acids. 
• Increased  K+  uptake. 
 
 
 
 
 INTRACELLULAR  REGULATION  OF  INSULIN  SECRETION
 Insulin  is  inturn  regulated  by  second  messengers  which  are  
located  intracellularly  like  Adenylate  cyclase  and  Phospholipase C.
Intracellular  regulation  of  insulin  secretion  by
cyclase 
 EPAC - Exchange  proteins  activated  by
 PKA - Protein  kinase  A.
26 
  cyclic  AMP.
 
 
 
 
 
 Adenylate  
 
  
 Intracellular  regulation  of  insulin  secretion  by
Phospholipase C. 
 Phospholipase C
generate  Inositol  triphosphate  and  Diacyglycerol.
IP3  mobilises  intracellular  calcium  from  endoplasmic  
reticulum. 
27 
  hydrolyses  Phosphoinositol  bisphosphate  to
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DAG  activates  protein  kinase  C.  Both  facilitate  insulin  
release. 
 
PATHOGENESIS  OF  DIABETES  MELLITUS: 
DIABETES  MELLITUS  TYPE  1: 
 The  pathogenesis  behind  the  development  of  Diabetes  Mellitus  
type - 1  is  autoimmune  destruction  of  the  isletic  pancreatic  beta  
cells. Although  it  manifests  itself  abruptly  in  young   individuals,  the  
process  is  a  chronic  one. 90%  of  the  beta  cells   are  destroyed  
before  the  clinical  manifestation  occurs. Several mechanisms  are  
found  to  cause  the  destruction  of  the  beta  cells. 
 Interaction  of  T-cells  with  the  B-cell  antigen  causes  major  
damage  to  the  beta  cells. TH1 subset  of  CD4+  cells  mediate   
macrophage  activation  and  resultant  cell destruction. Cytotoxic T cells 
of  CD8+  type  attack  the  beta  cells  directly  and  also through  
activating  macrophages  by  the  secreted  cytokines.  In a  group  of  
people  of  diabetes  mellitus  type 1  disease,  autopsy of  the  pancreas  
showed  inflammatory  infiltrate  contatining  CD4+  and  CD8+  cells. 
Cellular  necrosis  was  found  and  the  lesion  were called  insulinitis. 
The  major  cytokines  responsible  for  the  destruction  of  the  beta cells  
are  Interferon  gamma,  Tumour necrosis  factoralpha  and   
Interleukin - 1. 
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 Many  mouse  model  experiments  implied  the  antigenic  target  
as Insulin  Glutamic  acid  dehydroxylase (GAD), ICA-512/IA-2  and  a 
beta  cell  specific  zinc  transporter (ZnT-8). 
 
Genetic  considerations: 
 There  is  40 - 60%  concordance  between  identical  twins.  HLA 
DQA1*03001,  DQB1*0302,  DQB1*0201  have  been  found  to 
strongly  associated  than  any  othey  haplotype. They  are  present  in 
40%  of  children. The  gene  that  is  strongly  associated  with  DM   
type 1  is  located  in  chromosome  6  corresponding  to  HLA  region 
which  encodes  Major  Histocompatibility  Complex  Class  II. Atleast   
20  loci  have  been  mapped  for  the  genetic  predisposition.  
 Polymorphisms  in  the  insulin  gene  promoter  region, interleukin 
Receptor, CTLA-4 gene, PTPN22, CTLA4  are  some  of  them. HLA 
DQA1*0102, HLA DQB1*0602  offer  protection  against  the  Disease  
and  are  extremely  rare. Relatives  have  a  10 fold  high chance  of  
getting  the  disease. 
 
Environmental  factors: 
 Bovine  milk  proteins. 
 Nitrosourea  compounds. 
 Coxsackie,  Rubella  and  Enteroviruses. 
 DIABETES  MELLITUS  TYPE 
 Its  pathogenesis  revolves  around  Insulin  Resistance  and  
Abnormal Insulin  Secretion.
resistance  is The  forerunner  of  insulin  secretory  defect,  but  for  
diabetes  to  develop,  insulin  
Asians  and  South  Asians  have  predominantly  dysfunction  of  beta  
cells, while  Latin  Americans  have  insulin  resistance  as  the  main  
pathology. DM T2  is  charecterised  by  abnormal  fat  metabolis
insulin  resistance,  decreased  insulin  secretion  and  excessive  
glucose  production.
 
 
Insulin  resistance
It  is  charecterised  by  
 i)Decrease  in  tyrosine  kinase activity  of  insulin  receptor
 ii)Decrease  in  insulin  
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 The  defects  in  postreceptor  insulin  regulated   
dephosphorylation / phosphorylation  play  an  important  role  for  the 
development  of  insulin  resistance. It  is  also  caused  by  some   
adipokines  and  increased  production  of  free  fattyacids.  
 Skeletal muscles  are  affected  before  the  liver.  In  skeletal   
muscles  uptake  of  3 -O- methylglucose  which  is stimulated  by  
insulin  is  significantly  low  compared  to  normal   individuals.24-25 
There  is  significant  decrease  in  second  messenger  activity  mediated  
by  Insulin  Receptor  Substrate - 1 (IRS-1). Proximal  insulin  signaling  
is  downregulated.  Plasma  cell   differentiation  factor - 1 (PC-1) is  an  
intrinsic  inhibitor  of  insulin   receptor  tyrosine  kinase  activity.  It  is  a  
glycoprotein  with   ectonucleotide  pyrophosphate  activity. Muscle  
expression  of  PC - 1  has  negative  correlation  for  insulin  sensitivity.26  
There  is  a  strong association  between  PC-1 expression  for  insulin  
receptor   downregulation  than  with  decreased  expression  of  insulin  
receptor Protein-tyrosine  phosphatase-1B  has  negative  downregulative 
action on  the  phosphorylation  of  insulin  receptor  and  IRS-1.27-28There  
is   positive  association  between  insulin  resistance  andhepatic   
accumulation  of  fat. 
 Insulin  resistance  syndrome/Metabolic  syndrome  is  a  
symptomatic  constellation  including  insulin  resistance,  
DM T2  or IGT/IFG,  accelerated  cardiovascular  disease,  hypertension,  
central  or  visceral  obesity.
Peroxisome Proliferator  Activated  Receptor  Gamma.
 Many  medical  conditions  are  associated 
resistance.  Systemic  lupus  erythematosus, Renal  failure, Uremia, 
Cirrhosis  of  liver, Hemochromatosis, Thalassemia  in  association  with  
transfusion induced  iron  overload, 
few  of  them. 
 The  inhibitory  effects  of  chronic  hyperglycemia  on  action  and
secretion  of  insulin  has  been  termed  as  Glucose  Toxicity. Insulin 
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resistance  induced  by  hyperglycemia  includes  a  defect  in  insulin - 
stimulated  glycogen  synthesis  and  downregulation  of  the  glucose  
transport  system  by  hyperglycemia. 
 
Development  of  insulin  resistance: 
 First  phase :  Normal  plasma  glucose  despite  demonstrable             
insulin  resistance,  because  of  high  insulin  levels. 
 Second  phase : Worsening  of  insulin  resistance  leading  to  post  
prandial  hyperglycemia  despite  of  high  insulin  secretion. 
 Third  phase : There  is  no  change  in  the  level  of  insulin                         
resistance  but  fasting  hyperglycemia  occurs  because of  declining  
insulin  sectretion. 
 
Insulin  resistance  syndromes:29-30 
 Type  A - young  women, obesity, severe  hyperinsulinemia  and                 
features  of  hyperandrogenism. Undefined  defect  in  the                
pathway  of  insulin – signaling.31 
 Type B - middle - aged  women, severe  hyperinsulinemia,  
features  of hyperandrogenism  and  autoimmune  disorders.  
Autoimmune antibodies  against  insulin  receptor. Auto – stimulation  of   
the  receptor  leads  to  intermittent  hypoglycemia.  
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METABOLIC  SYNDROME: 
 The  New  International  Diabetes  Federation  defines  metabolic  
syndrome  as  Central  obesity  +  two  of  the  four  factors.32 
Hypertriglyceridemia   :  ≥ 150 mg/dl  or  specific  medication. 
Low  LDL  cholesterol :  < 40 mg/dl  for  men  and   < 50 mg/dl  for  
women. 
Hypertension (BP):  ≥ 130 mmHg (systolic)  or 
                                   ≥85 mmHg (diastolic)  or  specific  medication. 
Fasting  Plasma  Glucose :  ≥ 100 mg/dl  or  specific  medication  or   
                                         previously  diagnosed  Type  2  Diabetes. 
Central  obesity  is  defined  as  waist  circumference  > 90 cm  for   
South Asian  males  and  > 80 cm  for  South  Asian  females. 
 
Impaired  insulin  secretion: 
 Initially  the  first  phase  is  affected  that is  insulin  secretion  in   
response  to  glucose. Later  non  glucose  secretagogues  mediated   
insulin  secretion  is  also  affected. In contrast  to  90%  reduction  in  
beta  cell  function  present  in  Type  1  DM,  Type  2  DM is  
charecterised  by  50%  reduction. Fibrillar  amyloid  depositon following  
amylin  secretion  may  contribute  to  beta  cell  dysfunction. 
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Genetic  considerations: 
 In  contrast  to  type  1  disease  type  2  has  70-90%  concordance 
Between  identical  twins. There  is  40%  chance  for  the  child  to get  
the  disease  if  both  of  its  parents  are  affected. More  than  70  genes  
are  identified,  of  which  the  most  prominent  is  a  Transcription Factor 
7-like  2 gene  variant.  Genes  encoding  the  proteins  peroxisome  
proliferator - activated  receptor  gamma,  zinc transporter, IRS, calpain  
10, inward  rectifying  potassium  channel show  genetic  polymorphisms. 
 
MONOGENIC  FORMS  OF  DIABETES  MELLITUS:33 
 Mode  of  inheritance  is  Autosomal  Dominant. 
 Maturity  onset  diabetes  of  young (MODY)  is  associated  with   
mutation  in  the  specific  genes. 
 
MODY 1 - Hepatocyte  nuclear  transcription  factor (HNF) 4  alpha. 
MODY 2 - Glucokinase. 
MODY 3 - HNF 1 alpha.  
MODY 4 - Insulin  promoter  factor (IPF) 1. 
MODY 5 - HNF 1 beta.  
MODY 6 - NeuroD1.  
Transient  of  Permanent  Neonatal  Diabetes - ATP sensitive 
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Potassium  channel  subunits (Kir6.2  and  ABCC8)  and   
              Insulin  gene. 
 
RISK  FACTORS  FOR  DEVELOPMENT  OF  TYPE  2 
DIABETES  MELLITUS 
 
Family  history  of  diabetes. 
Obesity. 
Physical  inactivity. 
Race/ethnicity. 
Previously  identified  with  impaired  fasting  glucose,  impaired   
        glucose  tolerance,  or  a  HbA1c  of  5.7 - 6.4%. 
History  of  GDM  or  delivery  of  baby > 4kg. 
Hypertension. 
Polycystic  ovarian  syndrome  or  acanthosis  nigricans. 
History  of  cardiovascular  disease. 
HDL  cholesterol < 35 mg/dl  and/or  a Triglyceride > 250 mg/dl. 
 
CRITERIA  FOR  DIAGNOSIS  OF  DIABETES 
MELLITUS34 
1) Symptoms  of  diabetes  +  random  blood  glucose*  ≥ 200 mg/dl. 
2) Fasting  plasma  glucose**  ≥ 126 mg/dl. 
3) Hemoglobin  A1c ≥ 6.5%. 
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4) 2 - hour  plasma  glucose  ≥ 200 mg/dl  using  an  oral  glucose   
tolerance  test***. 
 
*Random  is  defined  as  without  regard  to  the  time  since  last 
  meal. 
**Fasting  is  defined  as  no  calorie  intake  for  a  time  period  of   
   atleast  8  hours. 
***The  test  should  be  performed  using  a  glucose  load  containing  
     the  equivalent  of  75 gram  anhydrous  glucose  dissolved  in   
     water. Not  recommended  for  routine  clinical  use. 
 
TREATMENT  OF  DIABETES  MELLITUS 
 
GOAL:35 
Eliminate  symptoms  of  hyperglycemia. 
Allow  the  patient  to  have  a  normal  lifestyle  as  much  as   
   possible. 
Eliminate  or  reduce  longterm  macro  and  microvascular  
   Complications. 
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INDEX GOAL 
HbA1c < 7.0% 
Preprandial  capillary  plasma  glucose 80 - 130 mg/dl 
Peak  postprandial  capillary  plasma  glucose < 180 mg/dl 
Blood  pressure < 140/90 mg/dl 
Low - density  lipoprotein < 100 mg/dl 
High - density  lipoprotein > 4o mg/dl in men 
> 50 mg/dl in women 
Triglycerides < 150 mg/dl 
 
SYMPTOMS: 
Thirst, dry  mouth. 
Polyuria. 
Nocturia. 
Change  in  weight ( usually  loss  of  weight) 
Lethargy,  fatigue. 
Blurring  of  vision. 
Balanitis,  pruritus  vulvae. 
Headache. 
Nausea. 
Hyperphagia  with  predilection  for  sweet  foods. 
Mood  change,  apathy,  irritability,  difficulty  in  concentration. 
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TREATMENT  
 
Type  1  Diabetes  Mellitus : 
 Insulin  therapy  to  replace  the  deficient  insulin. 
 
Type  2  Diabetes  Mellitus : 
Adequate  glycemic  control  can  be  achieved  by : 
Lifestyle  and  diet  control  in  50%. 
Oral  Hypoglycemic  Agents  in  20 - 30%. 
Insulin  therapy  in  20 - 30%. 
Regular  physical  activity,  Healthy  diet,  Avoidance  of  stress  
forms  the  first  step  in  the treatment  of  type  2  diabetes. 
Aim  of  dietary  management:36 
Good  glycemic control: 
Avoid  hypoglycemia  and  reduce  hyperglycemia. 
Assist  with  weight  management. 
Weight  loss  for  obese  and  overweight  individuals. 
Ensure  adequate  nutritional  intake. 
Reduce  the  risk  of  macro  and  microvascular  complications. 
Avoid  atherogenic  diets. 
Avoid  diets  that  aggravate  complications,  for  example  high   
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protein  intake  in  nephropathy. 
 
Recommended %  of  energy  intake: 
 
Carbohydrate : 45-60%. 
        Sucrose : upto  10%. 
Fat  ( total)    : < 35%. 
   Omega - 6  polyunsaturated : < 10% 
   Omega - 3  polyunsaturated : 140 gram  of  oily  fish  once  or  twice  
weekly. 
  Monounsaturated  :  10 - 20%. 
 Saturated              : < 10%. 
Protein : 10 - 15%. Not  to  exceed  
 1g/kg body weight/day. 
Fruits/Vegetables : 5  portions  daily. 
 
 
 
 
 
 
 
 
 ORAL  HYPOGLYCEMIC  AGENTS :
 
 
 
Maximum  HbA1c  reduction  is  done  by  Sulfonylureas  and  
Biguanides. 
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Regular  physical  activity  and  Medical  nutrition  therapy  
provide  greater  HbA1c  reduction  compared  with  other  oral  
hypoglycemic agents. 
 Regular  assessment  of  glycemic  control  is  essential  to  prevent  
shorterm  and  longterm  
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complications. 
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Biochemical  tests  used  for  monitoring  are  as  follows: 
Present  state  of  diabetes  control – Blood  glucose  monitoring. 
Retrospective  assessment : 
 Immediate  past(few  hours) - Urine  glucose  testing. 
 Recents  past (few  weeks) - Fructosamine,  Glycosylated  albumin. 
 Remote  past (few  months) - Glycosylated  hemoglobin. 
 Relation  between  HbA1c  and  mean  plasma  glucose  in   
Standardized  assays: 
 
HbA1c Mean  plasma  glucose (mg/dl) 
6% 126 
7% 154 
8% 183 
9% 212 
10% 240 
11% 269 
12% 298 
 
Self  Monitoring  of  Blood  Glucose  is  recommended  in: 
 
1) Patients  on  multiple  doses  of  insulin  therapy. 
2) Pregnancy. 
3) Patients  prone  to  recurrent  hypoglycemia. 
4) During  acute  illness  and  in  peri-operative  period. 
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Glycated  Hemoglobin (HbA1c): 
 Glycated  Hemoglobin  (HbA1c)  measurement  is  the  standard 
method  to  assess  the  long  term  control  of  diabetes. Non - enzymatic 
glycation  of  hemoglobin  is  increased  when  plasma  glucose  is  
consistently  elevated. The  half  life  of  erythrocytes  is 120  days. 
HbA1c  thus  reflects  the  glycemic  history  over  the  past 2-3 months. 
Out  of  this  value  50%  is  contributed  by  the  previous months  
glycemic  level. 
 
EMERGENCIES  IS  DIABETES  MELLITUS: 
 Diabetic  ketoacidosis, 
 Hyperglycemic  hyperosmolar  state. 
 Hypoglycemia. 
 
DIABETES  RELATED  COMPLICATIONS:37 
Macrovascular: 
 Coronary  heart  disease. 
 Cerebrovascular  disease. 
 Peripheral  arterial  disease. 
 
Microvascular: 
 Neuropathy 
 Autonomic. 
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 Sensory  and  motor. 
 Nephropathy (albuminuria  and  falling  renal  function). 
 Ocular  
 Macular  edema. 
 Retinopathy.  
 
Other: 
 Gastrointestinal  
 Gastroparesis. 
 Diarrhea. 
 Genitourinary 
 Uropathy. 
 Sexual  dysfunction. 
 Dermatologic. 
 Infectious. 
 Cataracts. 
 Glaucoma. 
 Hearing  loss. 
 Cheiroarthropathy. 
 Periodontal  disease. 
 Uncertain  relationship  to  hyperglycemia 
 Depression. 
  Obstructive  
 Fatty  liver  disease.
 Hip  fracture.
 Osteoporosis ( in  type  1  diabetes  mellitus)
 Cognitive  impairment  or  dementia.
 Low  testosterone  in  men.
 
HYDROXYCHLOROQUINE
 
 Hydroxychloroquine  and  its  progenor  Chloroquine  are  
nonbiologic drugs  used  mainly  in  the  treatment  of  malaria  and  in  
rheumatic  diseases. 
Rheumatic Drug. It  belongs  to  aminoquinolone  group  of  drugs. The  
first  drug  used  from  this  group  was  quinine,  but  due  to  its  toxicity  
chloroquine  and  hydroxychloroquine  were  developed.
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sleep  apnea. 
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It  is  a  well  tolerated  Disease  Modifying  Anti  
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Hydroxychloroquine  differs  from  chloroquine  by  a  
hydroxyethyl group  instead  of  an  ethyl  group  on  the  tertiary  amino  
nitrogen  of  the  chloroquine  sidechain.38 
 
MECHANISM  OF  ACTION: 
 It  is  a  weak  base  and  hence  can  pass  through  cytoplasmic 
membrane  inside  the  cytoplasmic  vesicles  and  accumulate  there. It  
increases  the  intravesicular  pH  to  6.0  from  4.0 thus  interfering  with  
the  acid  dependent  subcellular   functions. 
 This  increased  pH  is  noted  to  have  many  postulated  
immunoregulatory  effects  including  attenuation  of  antigen processing  
and  its  presentation; stabilization  of  lysosomal membranes; inhibition  
of  cell-mediated  cytotoxicity.39-40 
 Receptor  assembly  gets  disrupted  including  the  Major  
Histocompatibility  Complex  class  II  molecules,  since  the high  pH  in  
the  endoplasmic  reticulum  stabilises  the  MHC  protein  and  prevents  
its  displacement  by  low  affinity   autoantigens.41  
 Together  with  the  decreased  membrane  receptor  recycling  
there  is  downregulation  of  antigen  presentation.42 
 It  has  an  overall  inhibitory  effect  on  proinflammatory 
cytokines. Hydroxychloroquine  has  been  observed  to  block  
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Interleukin - 1,  Interleukin - 6,  Interferon  gamma  production  by  
monocytes.43-44 
 It  has  antioxidant  properties  and  hence  protects  the  tissue 
against damage  by  free  radicals.45 
 It  inhibits  platelet  aggregation  and  adhesion,  leading  to  ananti-  
thrombotic  effect.46-47 
 It  favours  lipid  profile  by  reducing  the  triglycerides, low 
density lipoproteins, total  cholesterol  and  very  low  densitylipoproteins  
in  particular  patients  on  corticosteroid  therapy  concomitantly.48 
 The  half-life  of  hydroxychloroquine  is  40  to  50  days  and  the   
plasma  levels  will  start  to  increase  gradually  and  equilibrate  in   3  
to  4  months.49 
 Most  of  the  drug  is  excreted  unchanged  in  urine. A  part  of  
the  drug  is  metabolized  to  a  desethyl  derivative. Rest  of  the  drug  is   
excreted  in  the  faeces.50 
 
NOVEL  EFFECTS  FAVOURING  ITS  USE  IN  
DIABETES: 
 The  first  described  antidiabetic  effect  of  Chloroquine  was  in  
the  year  1984,  in  a  diabetic  patient  with  severe  insulin  resistance  in 
whom  after  adding  Chloroquine  insulin  requirement  decreased   
drastically.51 
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 Hydroxychloroquine  decreases  the  plasma  glucose  levels  by  
the inhibition  of  insulin  degradation  inside  the  golgi  apparatus.52-53  
Animal  models  have  demonstrated  an  inhibitory  effect  exerted  by 
Hydroxychloroquine  on  insulin  metabolism,  including  reduction  in  
intracellular  insulin  degradation  and  an  increase  in  intracellular  
insulin  accumulation,  slowing  of  insulin  receptor  recycling  and   
stimulation  of  insulin  mediated  glucose  transport.60 
 There  is  a potential  ability  for  Hydroxychloroquine  to  decrease   
HbA1c  in  diabetic  patients  and  coexisting  Systemic  Inflammatory  
Disease.54 There  is  reduced  risk  of  incident  diabetes  in  Rheumatoid 
Arthritis  patients   even  after  glucocorticoid  use  and  control  of  
disease  activity.55 
 Hydroxychloroquine  has  been  shown  to  improve  peripheral  
insulin  sensitivity  and  insulin  secretion  in  invitro  and  animal  
studies. 
 Inflammation  has  been  considered  to  play  a  very  important  
inter- mediary  role  in  the  pathogenesis  of  a  number  of  co-existing  
diseases  including  diabetes. Interleukin - 6  and  C - reactive  protein  
are  the  two  sensitive  physiological  markers  of  associated  insulin  
resistance,  hyperglycemia,  overt  diabetes  mellitus  and  sub-clinical  
inflammation. Hydroxychloroquine  exerts  anti-diabetic  effect  by   anti-
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inflammatory  action  by  inhibiting  interleukin - 6  and  C – reactive  
protein  production.56 
 Adding  Hydroxychloroquine  to  either  Glibenclamide  or  Insulin  
in treating  refractory  noninsulin  dependent  has  resulted  in  a  fall  in 
HbA1c  by  3.3%  over  6  months  and  30%  less  insulin  dose.57 
 Similar  effects  were  observed  in  Sulfonylurea  refractory  
Diabetes Mellitus  Type  2  patients  treated  with  Hydroxychloroquine,  
where HbA1c  reduction  was  reported  as  1.02.58 
 In  patients  with  diabetes  and  coexisting  rheumatoid  arthritis  
and treated  with  Hydroxychloroquine0.66%  reduction  in  HbA1c  
levels is  reported.59 
 
INDICATIONS  FOR  USE: 
• Rheumatoid  arthritis. 
• Systemic  Lupus  Erythematosus. 
• Discoid  Lupus. 
• Sjogren’s  Syndrome. 
• Antiphospholipid  Syndrome. 
Miscellaneous: 
• Palindromic  rheumatism. 
• Childhood  dermatomyositis. 
• Eosinophilic  fasciitis. 
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• Erosive  arthritis. 
• Childhood  systemic  lupus  erythematosus. 
 
DOSAGE: 
• 200 mg twice - thrice  daily. 
• Maintained  at  a  dose  of  6.5 mg/kg/day or  less. 
 
TOXICITY: 
Ocular : 
• Retinopathy ( Bull’s  eye  maculopathy): 
• risk  factors : high dosage (>6.4 mg/kg/day), 
• longer  duration  of  use (>5 yrs), liver or  kidney  
• disease, age >60 yrs. 
• Corneal  opacity. 
 
Dermatologic : 
• Rash. 
• Photosensitivity. 
• Alopecia. 
• Depigmentation  of  hair. 
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Neuromuscular: 
Headache. 
Tinnitus  and  deafness. 
Irritability, insomnia  and  nightmares. 
  Neuromyotoxicity - Proximal  muscle  weakness, cardiac  myotoxicity 
                                Peripheral  neuropathy. 
Cardiovascular: 
 Conduction  defects  and  cardiomyopathy. 
Gastrointestinal: 
 Nausea, vomiting, abdominal  cramps  and  diarrhea. 
Pregnancy, fertility  and  lactation: 
 Category C, no  teratogenic  effects  reported, in  breast  milk  low  
concentration  is  secreted. 
 
Hydroxychloroquine  accumulates  is  melanin  containing  cells  
like  Skin  and  Retinal  pigment  epithelium  and  hence  the  toxicity. 
 
Toxicity  monitoring: 
   After  5-7 years  of  use  there  is  1%  risk  of  retinal  toxicity. 
   Similar  effect  is  observed  following  a  cumulative  dose  of   
  1000 gram. 
  Annual  eye  examination  should  be  done  from  5  years  of   
  treatment  initiation. 
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Contraindication: 
Previous  visual  field  or  retinal  changes  related  to   
4-aminoquinoline  agents  or  hypersensitivity  to  it. 
Severe  liver  disease  due  to  viral  hepatitis. 
 
RHEUMATOID  ARTHRITIS 
 A  chronic,  inflammatory  disease of  unknown  aetiology  
charecterised  by  symmetric, peripheral  arthritis. The  hallmark  
pathology  are  synovial  inflammation  and  proliferation, thinning  of  
articular  cartilage  and  focal  bone  erosions. It  is  treated  with  Non 
steroid  anti-inflammatory  drugs, Disease  Modifying  Anti   Rheumatic  
Drugs, Glucocorticoids, Anti – Tumor  Necrosis  Factor  Agents, and  
Biologicals. Hydroxychloroquine  is  used  for  its  anti –inflammatory  
and  immunomodulatory  action. 
 
SYSTEMIC  LUPUS  ERYTHEMATOSUS 
 It  is  a  autoimmune  disease. Cell  and  organ  get  damaged  
initially which  is  mediated  by  immune  complexes  and  tissue  binding  
auto antibodies. It  affects  almost  all organs. Treatment  is  with  
NSAIDS, Cyclophosphamide, Mycophenolate mofetil, 
Hydroxychloroquine, Biologics, and  Glucocorticoids. 
  
 
MATERIALS  
AND  
METHODS 
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MATERIALS  AND  METHODS 
 The  study  was  conducted  at  the  Department of  Rheumatology, 
Madras Medical College and Rajiv GandhiGovernment General Hospital, 
Chennai -600003. 
 
ETHICAL COMMITTEE APPROVAL: 
 Obtained.  
 
PATIENT CONSENT: 
 Obtained.  
 
DURATION OF THE STUDY: 
 6  months. 
 
STUDY DESIGN: 
 Observational  study. 
 
SAMPLE SIZE: 
 100  patients. 
 
INCLUSION CRITERIA: 
 1. Patients above 16 years of age. 
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 2. Patients with rheumatological disease. 
 3. Patients receiving hydroxychloroquine. 
 4. Patients receiving  similar drugs in the same dosage. 
 
EXCLUSION CRITERIA: 
 1. Paediatric patients. 
 2. Pregnant females. 
 3. Antenatal mothers. 
 4. Diabetic Ketoacidosis. 
 5. Critically ill patients. 
 6. Hematological disorders. 
 7. Any change in medications or their dose during the study period. 
 
SELECTION OF PATIENTS: 
 Patients  attending  rheumatology  outpatient  department  with  
newly  diagnosed  rheumatological  disease  are  selected  based  on  the   
inclusion  and  exclusion  criteria. 
 
DATA COLLECTION AND METHODS: 
 Patients  satisfying  the  inclusion  and  exclusion  criteria  are  
selected. Blood  samples  are  collected. Complete  blood  count,  Renal  
function test  and  Liver  function  test  are  done. Before  initiating  
Tablet  Hydroxychloroquineat  a  dose  of  200 mg  twice  daily, for  the   
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treatment  of  their  rheumatologicalillness,  baseline  HbA1c, Fasting 
bloodsugar,  Postprandial  blood  sugar  are  measured. Based  on  the   
results,  patients  are  grouped  into  one  of the  three  groups  namely, 
Diabetes  Mellitus,  Impaired  Glucose  Tolerance  and  Normal  glucose 
Tolerance  as  defined  by  American  Diabetes  Association. 
 Patients  are  followed  up  after  3  months.The  same  
investigations  are  repeated.  The  results  obtained  after3  months  of  
treatment  with Hydroxychloroquine  are  compared  with  the  
baselinevalues. The   results  are  subjected  to  statistical  analysis.  
 
STATISTICAL  ANALYSIS: 
 The  results  are  analysed  using  SPSS  software  version  21. 
Association  between the  two  variables  was  analysed  using  paired-   
sample  t  test.The  primary  efficacy  measures  were  the  mean  change   
in  HbA1c,  Fasting  blood  sugar  and  Postprandial  blood  sugar  from   
the  baseline  to  3  months.Statistical  significance  is  assumed  with   a  
p  value  of 0.05. 
SPONSORSHIP: 
 No 
 
CONFLIT OF INTEREST 
 None 
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Select 100 patients fulfilling the
inclusion & exclusion criteria
Obtain baseline HbA1c, FBS & PPBS
Group into Diabetes, IGT & NGT based on 
American Diabetes Association definition
Start Hydroxychloroquine
Obtain HbA1c, FBS & PPBS after 3 months
Analyse both the values by paired t test
 OBSERVATION 
                         DISEASE  DISTRIBUTION
 
 
SLE - Systemic Lupus Erythematosus
RA  - Rheumatoid Arthritis
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DISEASE  DISTRIBUTION 
 
 SLE RA 
Number  of 
Patients 
30 70 
 
In  our  study  group,  majority  of  patients  had  Rheumatoid  
Arthritis,  constituting  70%  of  the  study  population. 
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PREVALENCE  OF  DIABETES,  IGT  AND  NGT  IN  
THE STUDY  GROUP 
 
 
 
IGT  - Impaired  Glycemic  Tolerance 
NGT - Normal  Glycemic  Tolerance 
30
30
40
0
Diabetes IGT NGT
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PREVALENCE  OF  DIABETES,  IGT  AND  NGT  IN  
THE STUDY  GROUP 
 
Glycemic 
Status 
Diabetes IGT NGT Total 
Number of 
Patients 
30 30 40 100 
 
In  our  study,  majority  of  patients  were  from  the  group  of  
Normal Glucose Tolerance (40%). Rest  of  the  patients  were  equally   
distributed  among  the  other  two  groups. 
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SEX  DISTRIBUTION 
72
28
 
Female
Male
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SEX - WISE  DISTRIBUTION  OF  DIABETES, IGT, NGT 
 
SEX DIABETES IGT NGT TOTAL 
Male 10 9 9 28 
Female 20 21 31 72 
Total 30 30 40 100 
 
In  our  study  group  females  were  72%  and  males  were  28%. 
There is  a  female  preponderance  in  our  study  since,  connective  
tissue  disorders  are  more  common  in  female  population. 
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AGE -WISE  DISTRIBUTION  OF  DIABETES, IGT, NGT 
 
 
 
IGT  - Impaired  Glycemic  Tolerance 
NGT - Normal  Glycemic  Tolerance 
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AGE -WISE  DISTRIBUTION  OF  DIABETES, IGT, NGT 
 
Age  group 
(yrs.) 
Diabetes IGT NGT Total 
20-30 1 3 13 17 
30-40 12 17 16 45 
40-50 14 6 6 26 
50-60 3 4 5 12 
Total 30 30 40 100 
 
In  our  study  group  of  100  patients,  clustering  of  cases  were  
seen  in  the  30 - 50 yrs age group (71%). Of  this  30 - 40  yrs  group   
had  maximum percentage (45%) in  the  study  population. The  oldest   
patient  was  59  years  old  and  the  youngest  26  years  old. 
 
 
 
 
 DISTRIBUTION  OF  DIABETES
AMONG  MALES  AND  FEMALES
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DISTRIBUTION  OF  DIABETES, IGT  AND  NGT  
AMONG  MALES  AND  FEMALES 
 
Glycemic 
status 
Males Females 
Diabetes 10 35.72% 20 27.78% 
IGT 9 32.14% 21 29.17% 
NGT 9 32.14% 31 43.05% 
 
In  our  study  majority  of  females  were  from  the  group  of  
Normal Glucose  Tolerance (43.05%). Males  were  equally  distributed  
in  all the  three  groups.  
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GLYCEMIC  PROFILE  OF  SYSTEMIC  LUPUS 
ERYTHEMATOSUS  AND  RHEUMATOID  ARTHRITIS 
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GLYCEMIC  PROFILE  OF  SYSTEMIC  LUPUS 
ERYTHEMATOSUS  AND  RHEUMATOID  ARTHRITIS 
 
 Diabetes IGT NGT Total 
SLE 7 6 17 30 
RA 23 24 23 70 
Total 30 30 40 100 
 
 In  our  study  group,  majority  of  patients  with  Systemic  Lupus   
Erythematosus  belonged  to  the  group  of  Normal  Glucose  Tolerance. 
Patients  with  Rheumatoid  Arthritis  were  equally  distributed  in  all  
the  three  group.  
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Analysis  of  HbA1c  in  Diabetes  group 
 
Paired Samples Statistics 
 Mean N Std. Deviation 
Std. Error 
Mean 
 
PreHCQHbA1c 
6.749 55 1.1202 0.1510 
PostHCQHbA1c 6.387 55 .9524 0.1284 
 
 
Paired Samples Correlations 
 N Correlation Sig. 
 
PreHCQHbA1c & 
PostHCQHbA1c 
55 0.996 0.000 
 
 
 
Paired Samples Test 
 Paired Differences T df Sig. (2-
tailed) Mea
n 
Std. 
Dev
iatio
n 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upp
er 
 
PreHCQHbA1c - 
PostHCQHbA1c 
0.36
18 
0.19
39 
0.026
1 
0.3094 0.41
42 
13.8
40 
54 0.000 
 
In  the  study  group  containing  Diabetes patients, HbA1c  
obtained after  3  months  of  treatment  with  Hydroxychloroquine  is 
compared with  the  baseline  value. The  results  are analysed  using  
paired  t test. The  p  value  obtained  is  0.001  and  is  highly  
significant. 
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Analysis  of  HbA1c  in  IGT  group 
 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error Mean 
 
PreHCQHbA1c 6.242 100 1.0529 0.1053 
PostHCQHbA1c 5.952 100 0.8839 0.0884 
 
Paired Samples Correlations 
 N Correlation Sig. 
 PreHCQHbA1c & PostHCQHbA1c 100 0.993 0.000 
 
 
Paired Samples Test 
 
Paired Differences 
t df 
Sig. (2-
tailed) 
Me
an 
Std. 
Deviation 
Std. Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
 
PreHCQHbA1c - 
PostHCQHbA1c 
0.2
900 0.2028 0.0203 0.2498 0.3302 14.303 99 
0.000 
 
 
In  the  study  group  containing  Impaired  Glucose  Tolerance  
patients, HbA1c  obtained  after  3  months  of  treatment  with  Hydroxy 
chloroquine  is  compared  with  the  baseline  value. The  results  are 
analysed  using  paired  t  test. The  p  value  obtained  is  0.001  and  is  
highly  significant. 
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Analysis  of  HbA1c  in  NGT  group 
 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error 
Mean 
 
PreHCQHbA1c 6.242 100 1.0529 0.1053 
PostHCQHbA1c 5.952 100 0.8839 0.0884 
 
 
Paired Samples Correlations 
 N Correlation Sig. 
 PreHCQHbA1c & PostHCQHbA1c 100 0.993 0.000 
 
 
Paired Samples Test 
 
Paired Differences 
t df Sig. (2-
tailed) Mea
n 
Std. 
Deviati
on 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
 
PreHCQHb
A1c - 
PostHCQHb
A1c 
0.29
00 0.2028 0.0203 0.2498 0.3302 
14.30
3 99 0.000 
 
 In  the  study  group  containing  Normal  Glucose  Tolerance  
patients, HbA1c  obtained  after  3  months  of  treatment  with  Hydroxy 
chloroquine  is  compared  with  the  baseline  value. The  results  are  
analysed  using  paired  t  test. The  p  value  obtained  is  0.001  and  is  
highly  significant. 
 
 COMPARISON OF HbA1c
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 IN ALL THREE GROUPS
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Analysis  of  FBS  in  Diabetes group 
 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error Mean 
 
PreHCQFBS 147.164 55 31.6852 4.2724 
PostHCQFBS 136.745 55 27.0885 3.6526 
 
 
Paired Samples Correlations 
 N Correlation Sig. 
 PreHCQFBS & PostHCQFBS 55 0.994 0.000 
 
 
Paired Samples Test 
 Paired Differences t df Sig. (2-
tailed) Mean Std. 
Deviati
on 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
 
PreHCQFBS - 
PostHCQFBS 
10.418
2 
5.6131 0.7569 8.9007 11.9356 13.765 54 0.000 
 
 In  the  study  group  containing  Diabetes patients, FBS  obtained 
after  3  months  of  treatment  with  Hydroxychloroquine  is  compared  
with  the  baseline  value. The  results  are analysed  using  paired  t  test. 
The  p  value  obtained  is  0.001  and  is  highly  significant. 
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Analysis  of  FBS  in  IGT  group 
 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error 
Mean 
 
PreHCQFBS 132.810 100 29.8527 2.9853 
PostHCQFBS 124.370 100 25.1523 2.5152 
 
 
Paired Samples Correlations 
 N Correlation Sig. 
 
PreHCQFBS & 
PostHCQFBS 
100 .992 .000 
 
 
Paired Samples Test 
 Paired Differences t df Sig. (2-
tailed) Mea
n 
Std. 
Deviat
ion 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
 
PreHCQFBS - 
PostHCQFBS 
8.440
0 
5.862
6 
0.5863 7.2767 9.6033 14.39
6 
99 0.000 
 
 In  the  study  group  containing  Impaired  Glucose  Tolerance  
patients, HbA1c  obtained  after  3  months  of  treatment  with  
Hydroxychloroquine  is  compared  with  the  baseline  value. The  results  
are analysed  using  paired  t  test. The  p  value  obtained  is  0.001  and  
is  highly  significant. 
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Analysis  of  FBS  in  NGT  group 
 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error 
Mean 
 
PreHCQFBS 132.810 100 29.8527 2.9853 
PostHCQFBS 124.370 100 25.1523 2.5152 
 
  
Paired Samples Correlations 
 N Correlation Sig. 
 
PreHCQFBS & 
PostHCQFBS 
100 .992 .000 
 
Paired Samples Test 
 
Paired Differences 
t df Sig. (2-
tailed) Mean 
Std. 
Deviati
on 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
 
PreHCQFBS - 
PostHCQFBS 
8.440
0 5.8626 0.5863 7.2767 9.6033 14.396 99 0.000 
 
 In  the  study  group  containing  Normal  Glucose  Tolerance  
patients, HbA1c  obtained  after  3  months  of  treatment  with  Hydroxy 
chloroquine  is  compared  with  the  baseline  value. The  results  are 
analysed  using  paired  t  test. The  p  value  obtained  is  0.001  and  is  
highly  significant. 
 
 
 COMPARISON OF FBS IN ALL THREE GROUPS
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Analysis  of  PPBS  in  Diabetes group 
 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error 
Mean 
 
PreHCQPPBS 213.109 55 43.8966 5.9190 
PostHCQPPBS 206.909 55 29.8870 4.0300 
 
 
Paired Samples Correlations 
 N Correlation Sig. 
 
PreHCQPPBS & 
PostHCQPPBS 
55 0.701 0.000 
 
 
Paired Samples Test 
 Paired Differences t df Sig. (2-
tailed) Mean Std. 
Deviat
ion 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
 
PreHCQPPBS -         
      PostHCQPPBS 
6.200
0 
31.317
0 
4.2228 -2.2662 14.666
2 
1.468 54 0.148 
 
In  the  study  group  containing  Diabetes patients, PPBS  obtained  
after  3  months  of  treatment  with  Hydroxychloroquine  is  compared  
with  the  baseline  value. The  results  are analysed  using  paired  t test. 
The  p  value  obtained  is  0.148 and  is  not  significant. 
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Analysis  of  PPBS  in  IGT  group 
 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error 
Mean 
 
PreHCQPPBS 200.120 100 37.5847 3.7585 
PostHCQPPBS 196.150 100 25.9943 2.5994 
 
 
Paired Samples Correlations 
 N Correlation Sig. 
 
PreHCQPPBS & 
PostHCQPPBS 
100 .728 .000 
 
 
Paired Samples Test 
 
Paired Differences 
t df Sig. (2-
tailed) Mean 
Std. 
Deviati
on 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
 
PreHCQPPBS 
- 
PostHCQPPBS 
3.9700 25.7931 2.5793 -1.1479 9.0879 1.539 99 0.127 
 
In  the  study  group  containing  Normal  Glucose  Tolerance  
patients, PPBS  obtained  after  3  months  of  treatment  with  Hydroxy 
chloroquine  is  compared  with  the  baseline  value. The  results  are  
analysed  using  paired  t  test. The  p  value  obtained  is  0.127  and  is  
not  significant. 
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Analysis  of  PPBS  in  NGT  group  
 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error 
Mean 
 
PreHCQPPBS 200.120 100 37.5847 3.7585 
PostHCQPPBS 196.150 100 25.9943 2.5994 
 
 
Paired Samples Correlations 
 N Correlation Sig. 
 
PreHCQPPBS & 
PostHCQPPBS 
100 .728 .000 
 
 
Paired Samples Test 
 
Paired Differences 
t df Sig. (2-
tailed) Mean 
Std. 
Deviati
on 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
 
PreHCQPPBS 
- 
PostHCQPPBS 
3.9700 25.7931 2.5793 -1.1479 9.0879 1.539 99 0.127 
 
In  the  study  group  containing  Normal  Glucose  Tolerance  
patients, PPBS  obtained  after  3  months  of  treatment  with  Hydroxy 
chloroquine  is  compared  with  the  baseline  value. The  results  are  
analysed  using  paired  t  test. The  p  value  obtained  is  0.127  and  is  
not  significant. 
 
 COMPARISON OF PPBS IN ALL THREE GROUPS
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12.Descriptives 
 
Descriptive Statistics 
 N 
Minimu
m 
Maximu
m Mean 
Std. 
Deviation 
HbA1c - Before 
Therapy 100 5.0 8.8 6.242 1.0529 
FBS - Before 
Therapy 100 97 206 132.810 29.8527 
PPBS - Before 
Therapy 100 120 280 200.120 37.5847 
Valid N (listwise) 100     
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13. Descriptive Statistics 
 
 
N Minimum Maximum Mean Std. Deviation 
HbA1c - After 
Therapy 100 5.0 8.1 5.952 0.8839 
FBS - After 
Therapy 100 97 186 124.370 25.1523 
PPBS - After 
Therapy 100 141 260 196.150 25.9943 
Valid N (listwise) 100     
 
Mean value of  HbA1c before Hydroxychloroquine therapy - 6.242 
Mean  value  of  HbA1c  after  Hydroxychloroquine  therapy - 5.952 
Mean value of  FBS  before  Hydroxychloroquine  therapy- 132.810 
Mean value of  FBS  after  Hydroxychloroquine  therapy - 124.370     
Mean value of  PPBS  before  Hydroxychloroquine  therapy - 200.120 
Mean value of  PPBSafter  Hydroxychloroquine  therapy - 196.150 
 
 
 
 
 
  
 
 
DISCUSSION 
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DISCUSSION 
          An observational  study  was  conducted  in  Institute  of  
Rheumatology at Madras  Medical  College  and  Rajiv  Gandhi  
Government  General  Hospital, Chennai - 600003  for  a  period  of  6  
months. 
 100  patients  who  are  newly  started  on  Hydroxychloroquine  
therapy  for  their  rheumatological  illness  fulfilling  both  inclusion  and  
exclusion  criteria  are chosen.In  the  study  population  females  were  
72  and  males  were  28. 70  patients had  Rheumatoid  arthritis  and  30  
of  them  had  Systemic  lupus  erythematosus. 
 Routine  investigations  were  taken. Serum  glycated  hemoglobin  
was  determined using  high  performance  liquid  chromatography. 
Fasting  blood  sugar  was  measured  after  overnight  fasting  of  8  
hours  and  Postprandial  blood  sugar  was measured  2  hours  after  
breakfast. All  these  investigations  are  done  before  starting  the  
patient  on  Hydroxychloroquine.  The  patient  is  then  started  on  
Tablet  Hydroxychloroquine  200 mg  twice  daily  for  their  
rheumatological  illness. 
 The  patients  are  then  reviewed  after  3 months  of  treatment. 
The  same  parameters  are  measured  again  at  the  end  of  3  months. 
The  results  are  then  analysed  using  paired  t  test. 
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 Pareek A, Chandurkar N, Thomas N, et al. conducted  a  double - 
blind, double -  dummy, randomized, comparative, multicenter  study  in  
15  centers  across  India  between  December  2009  and  July  2013  on  
267  uncontrolled  type  2  diabetes patients, post  3 months  treatment  
with  glimepiride/gliclazide  and  metformin. 
 Hydroxychloroquine  was  started  on  400 mg  daily  for  6 
months. The  efficacy was  assessed  at  12  weeks  and  24  weeks  by  
measuring  HbA1c, Fasting  blood   sugar  and  Postprandial  blood  
sugar. At  the  end  of  12  weeks  and  24  weeks   all  the  three  
parameters  reduced  significantly  from  the  baseline  values. At  the  
end  of  12  weeks  and  24  weeks  the  reduced  values  were  HbA1c  - 
0.56%  & 0.87%, FBS - 17 mg/dl  &  14.22 mg/dl,  PPBS - 34.74 mg/dl  
&  31.86  mg/dl  respectively. The  result  was  compared  with  another  
set  of  patients  started  on pioglitazone. The  results  were  compared  
and  was  found  to  be  nonsignificant. 
 Laura  R.  Rekedal, Elena  Massarotti,  Rajesh  Garg  et  al.  
conducted  a  study   in  which  45  patients  taking   Hydroxychloroquine  
and  37  patients  taking   Methotrexate  for  Rheumatoid  arthritis  were  
chosen. HbA1c  was  measured  at  baseline  and  after  12  months  after  
starting  the  treatment. The  mean  reduction  in  HbA1c  from  the  
pretreatment  values  was  0.66%  in  the  Hydroxychloroquine and  
0.11%  in  the  Methotrexate  receiving  patients. 
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 In  our  study  100  patients  were  divided  into  3  groups  based  
on  the  American  Diabetes  Association  definition  of  Diabetes  into  
Diabetes, Impaired  glucose  Tolernce  and  Normal  Glucose  Tolerance. 
 At  the  end  of  3  months  mean  decrease  in  HbA1c  was  0.362,  
0.29  and  0.29% in  Diabetes,  Impaired  glucose  tolerance  and  Normal  
glucose  tolerance  patients   respectively. All  of  them  had  a  p  value  
of  0.001  and  was  highly  significant. 
 At  the  end  of  3  months  mean  decrease  in  Fasting  blood  
sugar  was  10.42   mg/dl,  8.44  and  8.44 mg/dl  in  Diabetes,  Impaired  
glucose  tolerance  and  Normal  glucose  tolerance  patients  respectively. 
All  of  them  had  a  p  value  of   0.001  and  was  highly  significant. 
 At  the  end  of  3  months  mean  decrease  in  Postprandial  blood  
sugar  was  6.2 mg/dl,  3.97and  3.97 mg/dl  in   Diabetes,  Impaired  
glucose  tolerance  and  Normal  glucose  tolerance  patients  respectively. 
The  p  value  in  Diabetes, patients, Impaired  glucose  tolerant  and  
Normal  glucose  tolerant  patients were  0.148, 0.127  and  0.127  
respectively  and  were  not  significant. 
 
  
  
 
 
LIMITATIONS 
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LIMITATIONS  OF  THE  STUDY: 
 
1. A  multicentric  study  with  a  larger  population  is  required  to  
confirm the  efficacy  of  Hydroxychloroquinein  decreasing  blood  
glucose. 
 
2. All  the  patients  were  receiving  Tablet  Prednisolone  30  mg  per  
day. The  effect  of  the  steroid  in  glucose  homeostasis  has  to  
be  taken  into  account. 
 
3. Anemia,  Hemoglobin S,  Uremia  and  Pregnancy  cause  change  
decrease  in  the  level  of  HbA1c. 
 
 
 
 
 
 
 
 
 
 
  
 
 
CONCLUSION 
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CONCLUSION 
 
 HbA1c  decreased  in  all  the  three  group  of  patients. The  
decrease  was  greatestamong  Diabetics  and  same  among  
Impaired  and  Normal  glucose  tolerant  patients. 
 
 Fasting  blood  sugar  decreased  in  all  the  three  group  of  
patients. The  decreasewas  greatest  among  Diabetics  and  same  
among  Impaired  and  Normal  glucose  tolerant  patients. 
 
 Postprandial  blood  sugar  decreased  in  all  the  three  group  of  
patients. The  decrease  was  greatest  among  Diabetics  and  same  
among  Impaired  and  Normal  glucose  tolerant  patients. 
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ANNEXURES 
  
PROFORMA 
 
NAME OF THE PATIENT : 
AGE / SEX    : 
IP/OP NUMBER   : 
OCCUPATION   : 
ADDRESS    : 
CONTACT NUMBER  : 
COMPLAINTS   : 
 
PAST HISTORY: 
 
DM  
SHT  
CKD  
CAD  
COPD  
SLE  
RA  
SS  
 
TREATMENT HISTORY : 
DRUG ALLERGY  : 
GENERAL EXAMINATION : 
VITALS     : 
SYSTEMIC EXAMINATION 
CARDIOVASCULAR SYSTEM: 
RESPIRATORY SYSTEM   : 
ABDOMEN         : 
 
CENTRAL NERVOUS SYSTEM: 
COMPLETE HEMOGRAM: 
LIVER FUNCTION TEST: 
RENAL FUNCTION TEST: 
DATE OF STARTING HYDROXYCHLOROQUINE: 
DATE OF BASELINE GLYCEMIC PROFILE: 
DATE OF FINAL GLYCEMIC PROFILE: 
TOTAL DURATION : 
COMPLIANCE : 
SIDE EFFECTS : 
 
ASSESSMENT : 
 
 
Age  
 
Gender  
 
Comorbidity 
 
       Date 
 
 
FBS 
 
PPBS 
 
HbA1
C 
          Baseline     
    Final    
 
 
  
  
  
   
INFORMATION SHEET 
We are conducting a study on “GLYCEMIC PROFILE OF 
PATIENTS ON HYDROXYCHLOROQUINE” among patients 
attending Rajiv Gandhi Government General Hospital, Chennai and for 
that your specimen may be valuable to us. 
 
The purpose of this study is to assess the efficacy of 
Hydroxychloroquine as an Oral Hypoglycemic Agent. 
 
We are selecting certain cases and if you are found eligible, we 
may be using your blood samples to do certain tests which in any way do 
not affect your final report or management. 
 
The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information will be 
shared. 
 
Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your 
decision will not result in any loss of benefits to which you are otherwise 
entitled. 
 
The results of the special study may be intimated to you at the end 
of the study period or during the study if anything is found abnormal 
which may aid in the management or treatment. 
 
 
 
 
Signature of the investigator                          Signature of the participant 
 
 
Date: 
Place: 
  
  
 CONSENT FORM 
 
Study Detail : “GLYCEMIC PROFILE OF PATIENTS ON 
 HYDROXYCHLOROQUINE”  
Study Centre : Department of RHEUMATOLOGY, Rajiv Gandhi 
Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification 
Number 
:  
Patient may check (☑) these boxes 
I confirm that I have understood the purpose of procedure for the above study. I 
have the opportunity to ask question and all my questions and doubts have 
been answered to my complete satisfaction. ❏ 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being 
affected. ❏ 
I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study and 
any further research that may be conducted in relation to it, even if I 
withdraw from the study I agree to this access. However, I understand that 
my identity will not be revealed in any information released to third parties 
or published, unless as required under the law. I agree not to restrict the use 
of any data or results that arise from this study. ❏ 
I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms. ❏ 
I hereby consent to participate in this study. ❏ 
I hereby give permission to undergo complete clinical examination , 
biochemical, immunological test. ❏ 
 
 
Signature of Investigator     Signature/thumb impression 
Study Investigator’s Name:    Patient’s Name and Address:
DR.A. MOHAMED ILIYAS 
  
 
  
 
 
 
 
MASTER CHART 
 
AGE SEX DIAGNOSIS DIABETES IGT NGT Pre - HCQ HbA1c Post - HCQ HbA1c Pre - HCQ FBS Post - HCQ FBS Pre - HCQ PPBS Post - HCQ PPBS
38 F SLE Y 7.5 7.1 169 157 244 232
49 F RA Y 7.9 7.4 180 166 253 241
53 M RA Y 5.4 5.3 109 106 183 180
41 F SLE Y 5.3 5.2 106 103 180 174
55 M RA Y 6.4 5.8 138 120 212 194
38 F RA Y 6.9 6.6 152 143 226 217
48 F RA Y 8.2 7.5 189 169 263 244
51 F RA Y 5.5 5.4 112 109 186 183
35 M SLE Y 5.5 5.4 112 109 186 183
57 F RA Y 8.5 7.7 198 174 272 247
36 F RA Y 5.4 5.3 109 106 183 180
47 M RA Y 7.7 7.2 174 160 247 235
27 F SLE Y 5.4 5.3 109 106 183 180
45 F RA Y 7.5 7.1 168 157 244 157
57 F RA Y 6.4 5.8 137 120 138 194
39 M SLE Y 6.8 6.5 149 141 223 141
26 F RA Y 5.2 5.2 103 103 174 174
55 F RA Y 5.3 5.3 106 106 180 180
48 M RA Y 7.7 7.2 174 160 247 235
35 F SLE Y 6 5.8 126 120 200 195
48 F RA Y 7.4 7 166 154 241 229
29 F RA Y 5 5 97 97 171 171
37 M RA Y 6.9 6.6 152 143 226 217
43 M SLE Y 5.1 5.1 100 100 174 174
46 F RA Y 7.7 7.3 174 163 247 163
58 M RA Y 6.4 5.8 137 120 212 194
57 F SLE Y 8.8 8.1 206 186 280 260
38 M RA Y 7.3 6.9 163 152 238 226
33 F RA Y 5.2 5.1 103 100 174 174
47 F RA Y 6.3 5.9 135 123 209 197
28 F SLE Y 5 5 97 97 171 171
39 M RA Y 7.2 6.8 160 149 235 223
38 F RA Y 5 5 97 97 171 171
49 F RA Y 8.6 7.9 200 180 274 253
38 M RA Y 6.2 5.8 132 120 206 194
34 M SLE Y 5.5 5.4 112 109 186 183
44 F RA Y 5.5 5.3 112 106 186 180
58 F SLE Y 5.2 5.1 103 100 177 174
48 F RA Y 7.6 7.1 171 157 244 232
39 F SLE Y 6 5.8 126 120 200 194
36 F RA Y 5.5 5.4 112 109 186 183
27 F RA Y 5.1 5.1 100 100 174 174
56 F RA Y 8.5 7.8 198 177 272 250
AGE SEX DIAGNOSIS DIABETES IGT NGT Pre - HCQ HbA1c Post - HCQ HbA1c Pre - HCQ FBS Post - HCQ FBS Pre - HCQ PPBS Post - HCQ PPBS
37 M RA Y 6.1 5.9 129 123 203 197
33 M RA Y 5.2 5.1 103 100 177 174
48 F SLE Y 5.1 5 100 97 174 171
37 M SLE Y 7.2 6.7 160 146 235 220
38 F RA Y 6.3 5.9 135 123 209 197
29 F RA Y 5.4 5.3 109 106 183 180
34 F SLE Y 5.1 5 100 97 174 171
49 F RA Y 7.6 7.1 171 157 244 232
37 F RA Y 5 5 97 97 171 171
27 F RA Y 5.5 5.4 112 109 186 183
56 F SLE Y 6.4 5.8 138 120 138 194
48 F RA Y 6.3 5.9 135 123 209 197
36 M RA Y 5.3 5.1 106 100 180 174
39 F RA Y 8.4 7.7 195 174 269 247
28 F SLE Y 5.4 5.2 109 103 183 171
35 M RA Y 6.2 5.8 132 120 132 194
26 F RA Y 5.3 5.1 106 100 180 174
37 F RA Y 6.1 5.9 129 123 203 197
49 F SLE Y 7.8 7.3 177 163 250 238
35 F SLE Y 5.4 5.1 109 100 183 174
46 F RA Y 6.3 5.9 135 123 209 197
48 F RA Y 6.3 5.9 135 123 209 197
36 M RA Y 6.8 6.5 150 141 223 215
48 F RA Y 8.4 7.9 195 174 269 253
59 M RA Y 5.4 5.1 109 100 183 174
36 M SLE Y 6.1 5.9 129 123 203 197
28 F RA Y 5.5 5 112 97 186 171
47 F SLE Y 7.4 7 166 154 241 229
36 F RA Y 5.5 5.1 112 100 186 174
38 F RA Y 6.1 5.9 129 123 203 197
38 F RA Y 7.2 6.8 160 149 235 223
29 F SLE Y 5.5 5.4 112 109 186 183
46 F RA Y 6.3 5.9 135 123 209 197
29 F SLE Y 5 5 97 97 171 171
37 F RA Y 6.1 5.8 129 120 203 194
33 F SLE Y 5.1 5 100 97 174 171
37 M RA Y 6.8 6.5 150 141 223 215
47 M RA Y 6.3 5.9 135 123 209 197
36 F RA Y 6.1 5.9 129 123 203 197
27 F RA Y 5.4 5.1 109 100 183 174
37 M RA Y 6 5.8 126 120 200 194
32 F SLE Y 5.2 5 103 97 177 171
48 F SLE Y 8.6 7.9 188 180 262 253
29 F RA Y 5.9 5.7 123 117 197 191
AGE SEX DIAGNOSIS DIABETES IGT NGT Pre - HCQ HbA1c Post - HCQ HbA1c Pre - HCQ FBS Post - HCQ FBS Pre - HCQ PPBS Post - HCQ PPBS
49 F SLE Y 5.2 5 103 97 177 171
33 F RA Y 5.3 5.2 106 103 180 177
27 M SLE Y 5.8 5.6 120 114 120 188
29 M RA Y 6.7 6.4 146 138 220 212
37 F RA Y 6 5.8 126 120 126 194
38 M SLE Y 5 5 97 97 171 171
38 F RA Y 7.5 7 169 154 244 229
28 F RA Y 5.8 5.6 120 114 120 188
45 M RA Y 5 5 97 97 171 171
36 F RA Y 6.2 5.8 132 120 132 194
38 F SLE Y 6 5.8 126 120 200 194
34 F RA Y 5.9 5.7 123 117 123 191
37 F RA Y 5.9 5.7 123 117 123 191
